Effect of Renin-Angiotensin System Blockade on Soluble Klotho in Patients with Type 2 Diabetes, Systolic Hypertension, and Albuminuria
Effect of Renin-Angiotensin System Blockade on Soluble Klotho in Patients with Type 2 Diabetes, Systolic Hypertension, and Albuminuria
复制标题
DOI：
10.2215/cjn.02700313
复制
发表时间：
2013-11-07
影响因子：
9.8
通讯作者：
Gnudi, Luigi
中科院分区：
文献类型：
--
作者：
Karalliedde, Janaka;Maltese, Giuseppe;Gnudi, Luigi
背景与目的可溶性Klotho是一种抗衰老的磷酸化蛋白，具有血管-肾保护作用。体外和体内研究表明，肾素-血管紧张素系统（RAS）阻断增加可溶性Klotho水平。RAS阻滞剂对糖尿病肾病（DKD）患者可溶性Klotho的影响尚不清楚。设计、环境、参与者和测量在一所大学医院中心进行的一项随机对照临床试验（ClinicalTrials.gov编号NCT001715, 2003年3月至2006年9月）的二次分析中测量了血浆可溶性Klotho。76例2型糖尿病合并DKD患者（均伴有蛋白尿和血清肌酐）
Background and objectivesSoluble Klotho is an anti-aging phosphaturic protein associated with vascular-renal protection. In vitro and in vivo studies have demonstrated that renin-angiotensin system (RAS) blockade increases soluble Klotho levels. The effect of RAS blockers on soluble Klotho in patients with diabetic kidney disease (DKD) is unknown.Design, setting, participants, & measurementsPlasma-soluble Klotho was measured in a secondary analysis of a randomized controlled clinical trial performed at a single university hospital center (ClinicalTrials.gov number NCT001715, from March 2003 to September 2006). Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine